Our approach
GCC deploys catalytic capital. This means we make investments that accept disproportionate risk or concessionary returns compared to conventional investors in order to generate positive impact. Our catalytic capital is used in blended finance transactions to crowd in private investment. By blending different types of capital (grants, debt, equity), our aim is to address market failures in the investment ecosystem and create opportunities for more private and return-seeking impact investors to support the scale-up of global health innovations.
Why it matters
The global innovation financing landscape faces persistent gaps, particularly for innovations serving low-resource settings. Traditional grant funding alone often proves insufficient for scaling proven solutions, while commercial capital typically seeks higher returns or lower risk profiles than don’t align with the profiles of early-stage health enterprises operating in challenging markets.
Blended finance bridges this divide by strategically combining different capital types to:
Bridge the “valley of death“
Support promising innovations through the critical gap between proof of concept and scale
De-risk investments
Unlock additional investment that would otherwise not be possible
Preserve impact integrity:
Enable companies to maintain focus on underserved populations while building sustainable models
Our financing toolkit
GCC is committed to providing founder-friendly financing tailored to the needs of early-stage social enterprises. We have tested a variety of innovative financial tools ranging from repayable grants to forgivable loans, results-based financing to royalty-based loans to SAFE notes. Our aim is to provide the most appropriate form of financing that will enable companies to transition to scale, maximize their impact and attract additional investment.
